Compare Abeona Therapeutics Inc (ABEO) vs Freshworks Inc (FRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Freshworks Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Freshworks Inc trades at $10.26 (market cap $2.87B). The key difference: Freshworks Inc is far larger — about 7.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | FRSH | |
|---|---|---|
Market Cap | $373.32M | $2.87B |
Sector | Health | Technology |
52-Week High | $7.23 | $15.36 |
52-Week Low | $4.17 | $6.88 |
Enterprise Value | $228.22M | $2.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Freshworks (FRSH) trades at $10.38, up 0.39% with a bullish technical signal. The company shows strong revenue growth from $498M in 2022 to $839M in 2025, achieving profitability with a net margin of 20.69%. Recent news highlights AI-driven service platform adoption, including Vanquis selecting Freshservice. Analyst consensus is split evenly between Buy and Hold ratings, with no Sell recommendations.
The outlook is positive due to accelerating revenue growth and expanding margins, though high EV/EBITDA of 48.15 suggests premium valuation. Risks include competitive pressures in SaaS and execution challenges in sustaining growth. Upside potential exists if the company maintains its earnings beat trend and capitalizes on AI integration demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
